Skip to main content

Table 1 Patient characteristics

From: Short-duration, submaximal intensity exercise stress combined with adenosine triphosphate decreases artifacts in myocardial perfusion single-photon emission computed tomography

 

Total

Group

p Value

A

A + 25 W

A + 35 W

A + 45 W

n = 109

n = 23

n = 34

n = 28

n = 24

Age, years

70 ± 10

75 ± 9

68 ± 10

69 ± 10

71 ± 8

0.056

Male, %

41

48

32

39

50

0.508

Previous MI, %

4

13

3

0

0

0.051

Previous PCI, %

16

39

12

11

4

0.051

Cerebrovascular disease, %

17

31

7

14

25

0.071

Peripheral artery disease, %

8

22

3

7

4

0.061

Hypertension, %

62

73

65

54

58

0.479

Dyslipidemia, %

57

68

62

46

54

0.051

Diabetes mellitus, %

41

46

38

46

33

0.782

Atrial fibrillation, %

5

9

3

7

0

0.445

Current Smoking, %

15

23

15

11

13

0.715

Laboratory data

Hb, g/dL

13.6 ± 1.7

12.7 ± 1.7

13.6 ± 1.4

14.1 ± 1.9

13.9 ± 1.8

0.051

HbA1c, %

7.8 ± 2.6

6.7 ± 1.2

8.2 ± 2.7

8.4 ± 3.2

7.4 ± 2.5

0.216

UA, mg/dL

5.4 ± 1.5

5.1 ± 0.8

5.2 ± 1.5

5.8 ± 1.8

5.6 ± 1.8

0.415

LDL-C, mg/dL

122 ± 35

108 ± 29

122 ± 30

139 ± 35

113 ± 41

0.036

HDL-C, mg/dL

54 ± 26

53 ± 15

61 ± 41

51 ± 10

48 ± 20

0.493

Creatinine, mg/dL

0.92 ± 0.64

1.23 ± 1.15

0.77 ± 0.21

0.81 ± 0.37

0.97 ± 0.45

0.054

BNP, pg/mL

49 (22, 78)

58 (22, 208)

48 (23, 68)

59 (15, 65)

40 (11, 63)

0.067

Medications

ADA, %

22

14

27

29

17

0.167

ATA, %

22

36

27

11

17

0.192

β blocker, %

14

14

18

18

4

0.440

CCB, %

46

55

47

46

38

0.634

Diuretics, %

8

14

6

11

4

0.374

Nitrates, %

7

14

9

7

0

0.636

RAS-I, %

37

36

27

36

54

0.075

Statin, %

41

57

44

21

42

0.462

  1. Data are mean ± SD or percentage except for BNP level (median, 25–75%)
  2. MI myocardial infarction, PCI percutaneous coronary intervention, Hb hemoglobin, UA uric acid, LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol, BNP brain natriuretic peptide, ADA antidiabetic agents, ATA antithrombotic agents, CCB calcium-channel blocker, RAS-I renin-angiotensin system inhibitor